The UK regenerative medicine company, Intercytex Group Plc, is moving forward with a pivotal Phase 3 trial of its lead product for chronic wounds and anticipates filing a biologic licence application for the product with the US Food and Drug Administration in the second half of 2009.
ReNeuron Group Plc has asked for clearance from the UK regulator to test its stem-cell therapy for stroke in man for the first time, having failed thus far to get permission for a human study from the US Food and Drug Administration.
Shares of ReNeuron Group Plc fell 2.25 pence or 16.4% to 11.50 pence on London’s Alternative Investment Market (AIM) following the company’s disclosure that the US Food and Drug Administration (FDA) has once again delayed its Phase 1 clinical study of its stem-cell therapy for patients with stroke, ReN001.
Stem Cell Sciences Plc (SCS) is closing its office in Edinburgh, UK, streamlining its operations in Melbourne, Australia, and moving its operational base to the Babraham Research Campus in Cambridge, UK, where management will focus on negotiating research collaborations with pharmaceutical companies.